Cost-Effectiveness Analysis of a Quadrivalent Human Papilloma Virus Vaccine in Mexico

This publication has 26 references indexed in Scilit:

• Diferencias regionales en la mortalidad por cáncer de mama y cérvix en México entre 1979 y 2006
  Salud Pública de México, 2009
• Decreasing Cervical Cancer Mortality in Mexico: Effect of Papanicolaou Coverage, Birthrate, and the Importance of Diagnostic Validity of Cytology
  Cancer Epidemiology, Biomarkers & Prevention, 2008
• Chapter 18: Public health policy for cervical cancer prevention: The role of decision science, economic evaluation, and mathematical modeling
  Vaccine, 2006
• Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination
  Vaccine, 2006
• Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
  The Lancet Oncology, 2005
• Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs
  JAMA, 2003
• Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis
  British Journal of Cancer, 2003
• A Controlled Trial of a Human Papillomavirus Type 16 Vaccine
  New England Journal of Medicine, 2002
• Safety and Immunogenicity Trial in Adult Volunteers of a Human Papillomavirus 16 L1 Virus-Like Particle Vaccine
  JNCI Journal of the National Cancer Institute, 2001
• Papillomavirus-Like Particle Vaccines
  JNCI Monographs, 2000